Cerus (CERS) Bullish View Reiterated at FBR as FDA Expands Protection Against Transfusion-Transmited Zika

August 26, 2016 12:13 PM EDT
Get Alerts CERS Hot Sheet
Price: $4.23 -1.4%

Rating Summary:
    5 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 32 | Down: 30 | New: 8
Trade CERS Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

FBR Capital analyst Thomas Yip reiterated an Outperform rating and $10 price target on Cerus (NASDAQ: CERS) after the FDA issued a revised industry guidance document recommending that donated whole blood and individual blood components collected in all U.S. states and U.S. territories should be tested for Zika virus (ZIKV) or treated with a pathogen reduction device such as Cerus' INTERCEPT.

Yip commented, "This revision represents an expansion to an earlier industry guidance (issued on February 16, 2016) recommending that ZIKV testing or pathogen inactivation should be implemented in areas with active ZIKV transmission. Although the primary method of ZIKV transmission is through the Aedes aegypti mosquito, we think this revision highlights the FDA's increasing efforts to safeguard the U.S. blood supply in order to prevent a widespread ZIKV outbreak via blood transfusions. INTERCEPT remains the only FDA-approved method to inactivate ZIKV in collected platelets and plasma, with some ZIKV tests currently in early development under Investigational New Drug applications that are allowed to be used under the FDA's guidance. We think increasing public awareness regarding a potential ZIKV outbreak and overall blood supply safety could lead to INTERCEPT's accelerated adoption by major blood providers such as the American Red Cross. We reiterate our Outperform rating."

For an analyst ratings summary and ratings history on Cerus click here. For more ratings news on Cerus click here.

Shares of Cerus closed at $6.60 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Add Your Comment